Skip to content

EUS-Guided Choledochoduodenostomy Using Covered Self-Expandable Metallic Stents with a Thin Delivery System Versus ERCP for First-Line Biliary Drainage in Unresectable Malignant Distal Biliary Obstruction: A Multicenter Randomized Trial

Comparison of endoscopic ultrasound-guided choledochoduodenostomy and endoscopic retrograde cholangiopancreatography in first-line biliary drainage for malignant distal bile duct obstruction: A multicenter randomized controlled trial - Comparison of endoscopic ultrasound-guided choledochoduodenostomy and endoscopic retrograde cholangiopancreatography for malignant distal bile duct obstruction : A multicenter randomized controlled trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000041343
Enrollment
95
Registered
2020-09-01
Start date
2020-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A malignant distal biliary obstruction that is unresectable or presents a very high surgical risk

Interventions

Transpapillary biliary drainage (ERCP) Endoscopic ultrasound biliary drainage (EUS-BD)

Sponsors

Wakayama-Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) 20 years old or over 2) Radiological diagnosis (with or without pathological confirmation) of malignancy, and presence of a malignant distal biliary obstruction and dilation of the upstream bile duct that is unresectable or presents a very high surgical risk 3) Written consent obtained following adequate explanation of the study aims, design, and procedures.

Exclusion criteria

Exclusion criteria: 1) Radiological evidence of gastric outlet obstruction on CT, 2) Hilar biliary obstruction, 3) Surgically altered anatomy 4) ECOG performance status of 4, 5) Poorly controlled ascites, 6) History of endoscopic sphincterotomy (EST), 7) Biliary stenting, 8) Serious complication involving another organ, 9) Uncorrectable coagulopathy and/or thrombocytopenia, 10) Any other condition or situation determined by a study investigator to represent a reason for ineligibility.

Design outcomes

Primary

MeasureTime frame
Stent patency rate at 180 days after treatment

Secondary

MeasureTime frame
Procedure success rate, clinical improvement rate, incident rate, procedure time, success rate of re-intervention, rate of successful stenting without dilatation (EUS-BD group only), survival time, and percentage of post-drainage chemotherapy

Countries

Japan

Contacts

Public ContactMasahiro Itonaga

Wakayama-Medical University Second Department of Internal Medicine

kitano@wakayama-med.ac.jp073-441-0627

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026